How should PMS and PMDD be understood and treated differently based on how severe they are?

Premenstrual Syndrome (PMS) and its severe variant, Premenstrual Dysphoric Disorder (PMDD), represent a cyclical neuroendocrine-psychiatric phenomenon affecting a significant proportion of individuals of reproductive age. Despite its prevalence, management remains fragmented, often oscillating between minimalization and over-medicalization. This paper proposes a paradigm shift from a symptom-checklist model to a “Premenstrual Spectrum” model, integrating recent neurobiological findings with psychosocial determinants. It advocates for a staged, personalized management algorithm tailored to symptom severity, functional impairment, and patient preference. A narrative review was conducted synthesizing literature from October 2023 to November 2025, focusing on randomized controlled trials, systematic reviews, and novel pathophysiological studies. Emerging evidence solidifies the role of allopregnanolone sensitivity, GABAergic modulation, and genetic polymorphisms (e.g., ESR1, BDNF) in etiology. Low-grade inflammation and gut-brain axis dysregulation are identified as potentiating factors. Non-hormonal interventions, particularly selective progesterone receptor modulators (SPRMs) and novel GABA-A receptor modulators, show significant promise. Cognitive-behavioral therapy (CBT) and mindfulness-based interventions demonstrate robust efficacy for mood and cognitive symptoms. PMS/PMDD is a legitimate, multifactorial condition requiring a nuanced clinical approach. A biopsychosocial framework combined with a step-care treatment model—ranging from lifestyle and behavioral interventions to targeted pharmacological therapy—optimizes outcomes. Future research must prioritize non-hormonal targets and culturally adapted management tools.

Reproduced under CC-BY.